$5.50
Value $285M
EBS and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$5.50
Value $285M
$349.91
Value $318B
Emergent BioSolutions (EBS) has a market value of $285M and UnitedHealth (UNH) $318B. Over the last year, with dividends, EBS moved -44.5% and UNH +24.3%. Dividend yield: EBS none, UNH 2.59%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EBS$285M
UNH$318B
UNH is 1,115 times EBS
Revenue, 12 months
EBS$649M
UNH$450B
UNH is 693 times EBS
Net income, 12 months
EBS-$261M
UNH$15.9B
Operating margin
EBS-27.7%
UNH5.3%
33.0 points apart
ROIC
EBS-13.7%
UNH11.3%
25.0 points apart
P/E
EBS–
UNH20.0
Dividend yield
EBS0.0%
UNH2.6%
2.6 points apart
5-year return
EBS-86.3%
UNH-5.1%
81.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EBS-86.3%
UNH-5.1%
| Period | EBSWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -44.5%Price -44.5% | +24.3%Price +21.1% |
| 3 years since November 17, 2023 | +173.7%+39.9% a yearPrice +173.7% | -22.6%-8.2% a yearPrice -27.3% |
| 5 years since November 16, 2021 | -86.3%-32.8% a yearPrice -86.3% | -5.1%-1.0% a yearPrice -13.3% |
| 10 years since November 18, 2016 | -80.9%-15.3% a yearPrice -80.9% | +207.9%+11.9% a yearPrice +160.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
EBSEmergent BioSolutionsUNHUnitedHealth
| Price | $5.50 | $349.91 |
|---|---|---|
| Market value | $285M | $318B |
| Enterprise value (EV) | $617M | $363B |
| P/E | – | 20.0 |
| P/E, 5-year median | – | 25.0 |
| P/B | 0.9 | 3.1 |
| EV/EBIT | – | 15.2 |
| Free cash flow yield | 66.2% | 7.2% |
| Revenue, 12 months | $649M | $450B |
|---|---|---|
| Net income, 12 months | -$261M | $15.9B |
| Free cash flow, 12 months | $188M | $22.8B |
| Earnings per share, 12 months | -$5.02 | $17.52 |
| Revenue growth, year on year | -28.8% | 11.8% |
| Revenue growth a year, past | -13.7%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | -30.4%over 5 years | -3.8%over 5 years |
| Gross margin | 48.4% | 88.3% |
|---|---|---|
| Operating margin | -27.7% | 5.3% |
| Net margin | -40.2% | 3.5% |
| ROIC | -13.7% | 11.3% |
| ROE | -57.1% | 15.5% |
| Cash | $176M | $28.5B |
|---|---|---|
| Total debt | $514M | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | -4.0× | 6.2× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | 8.7% | 1.8% |
| Shareholder yield | 8.7% | 4.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($318B) is about 1,115.4 times Emergent BioSolutions ($285M), at today's prices.
Since November 18, 2016, EBS's price moved -80.9% and UNH's +160.7%. With dividends: EBS -80.9% (-15.3% a year), UNH +207.9% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Emergent BioSolutions and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
Over the last twelve months, the net margin was -40.2% for Emergent BioSolutions and 3.5% for UnitedHealth, and the operating margin -27.7% and 5.3%. Revenue was $649M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.